1-4 months of pharmaceutical operation continued to good, pharmaceutical companies will plug in the information wings to take off

Pharmaceutical Network Market Analysis: In January-April this year, the operation of the pharmaceutical manufacturing industry continued to be good, the total profit and industrial value added above the scale significantly better than the average manufacturing industryIn terms of data performance, in terms of the operation of the pharmaceutical manufacturing industry, total profits in the pharmaceutical manufacturing industry fell by 7.4% YoY in January-April, a decline of 19.4 percentage points, a decrease of 8.3 percentage points from January to Marchfrom January to April the operation of medicine continued to be good (Photo: Pharmaceutical Network)pharmaceutical industry is an important part of the national economyWith the development of economy and the improvement of residents' living standards, China's pharmaceutical industry has shown a sustained and good trend of development, and the status of the pharmaceutical industry has gradually improvedThe industry says China has been introducing corresponding industrial support policies to support the development of the domestic pharmaceutical industryIn the future, China's pharmaceutical industry will continue to maintain growth, in the national economy will continue to improve the statusespecially in the research and development of new drugs, China has attached great importance to in recent yearsThe birth of a new drug, will be possible to fundamentally change the treatment of a disease, new drug research and development, and thus become a measure of a country's comprehensive scientific and technological strength of an important indicatorOver the past ten years, China attaches great importance to the research and development of new drugs, the implementation of "major new drug creation" and other major special projects, invested a lot of money, issued a series of new drug research and development policiesconform to the policy trend and market prospects, China's pharmaceutical listed companies are steadily growing investment in research and development, becoming the focus of capitalFrom the securities market point of view, many of the marketed pharmaceutical companies with the ability to innovate and deep research may usher in a stronger opportunityTake Shanxi Zhendong Pharmaceutical Co., Ltd., a large domestic integrated pharmaceutical company, for example, its recent performance is active, the capital side is strong, the attention of institutional funds has steadily increasedthe era of innovative drugs, the major pharmaceutical companies began to increase the pace of layout in the various areas of innovative drugs, hoping that early layout early to occupy market shareAmong them, Hengrui Pharmaceuticals, Pharmaceutical Ming-Kangde, Zhifei Bio and other sub-leaders continue to increase investment in innovative research and development, strengthen their own in the field of innovative medicine moatIn addition, Lizhu Medicine, which is home to Chinese medicine needles, has also been forced to transform into the field of innovative medicines in recent years, and has increased its investment in asset salesnew drug research and development has been the focus of the pharmaceutical and chemical industry, in recent years, with the policy support and enterprise investment, China's pharmaceutical industry overall development is good, new drugs, especially "life-saving drugs" market speed significantly accelerated, but in the new drug research and development transformation and patient-toability, some problems need to be brokenas the industry pointed out that in the information-based era of big data, how pharmaceutical companies seize the key effective information, so that new drug research and development is more than half the work is a very concern"In the process of new drug research and development, different research and development objectives have different intelligence needs, different stages of research and development to produce different pharmaceutical information, quickly and comprehensively grasp research and development information, is a strong guarantee for the smooth progress of research and development", therefore, China's pharmaceutical industry information, intelligence level needs to be acceleratedto the application and transformation of information-based achievements in the process of product research and development, China's pharmaceutical enterprises pay more and more attentionSuch as Hengrui Pharmaceuticals, for example, in the development of new drugs in a large number of the use of hundred-o-knowledge information productsIt is reported that in the clinical trial stage of several drugs, Hengrui Pharmaceuticals adopted the BAIO-Knowledge EDC system, medical coding system (MedCoding) and clinical data whole process management system (CDTMS), with scientific information means instead of manual lying the collection and management of clinical trial data, efficient and convenient, and not easy to make mistakes"The use of baiozhi information products not only guarantees the quality of clinical trial data, but also significantly shortens the time of clinical trials (especially pre-launch preparation), which has won valuable time for the development of the project and the launch of new drugs." The person involved saidNow, China's support for the development of innovative drugs continue stousan, pharmaceutical enterprises should grasp the development opportunities, the information technology better applied to new drug research and development, so as to better promote the development of the pharmaceutical industryData show that in January-April this year, the pharmaceutical manufacturing industry continued to perform well, total profits and above the value added of the industry significantly better than the average manufacturing industryI believe that with the continuous progress and development of technology, China's pharmaceutical industry will be more rapid development, the status of the pharmaceutical industry will be greatly enhanced